
Gail Naughton, PhD
Medical Device Development and Commercialization Expert
Career Highlights
Dr. Gail Naughton is a pioneering figure in the field of regenerative medicine, with nearly 35 years of extensive research and innovation in tissue engineering. As the Founder, CSO, and CBDO of Histogen, she has developed a method for creating hypoxia-induced multipotent stem cells that produce both soluble and insoluble extracellular matrices, which have multiple aesthetic and therapeutic applications. Her lead drug was recently in mid-stage clinical trials for hair growth, and her skin care product, ReGenica, was acquired by Allergan for the medical market in 2017. In 2024 Allergan acquired the rights to all of Histogen's technology. Dr. Naughton holds over 135 U.S. and foreign patents and has founded two regenerative medicine companies, showcasing her significant contributions to the industry.
Dr. Naughton co-founded Advanced Tissue Sciences (ATS) and co-invented its core technology. At ATS, she held various key management positions, including President, Chief Operating Officer, Chief Scientific Officer, and Principal Scientist. She oversaw the design and development of the world’s first up-scaled manufacturing facility for tissue-engineered products, established corporate development and marketing partnerships with companies such as Smith & Nephew, Medtronic, and Inamed Corporation, and was pivotal in raising over $350 million from public markets and corporate partnerships. Dr. Naughton successfully brought four products from concept through FDA approval and market launch. Her extensive publication record and frequent speaking engagements further highlight her expertise and influence in the field. In recognition of her groundbreaking work, she received the 27th Annual National Inventor of the Year award from the Intellectual Property Owners Association.
Education
-
MS and PhD: NYU Medical
-
MBA: UCLA